Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT07234032 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT07234032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07234032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Insmed Incorporated
Phase
Phase 3
Overall status
Recruiting
Start date
July 20, 2026
Completion date
January 22, 2031
Enrollment
344 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, pulmonary hypertension